On November 22, the "Fourth China Health Industry Development Conference and Golden Cane Award Ceremony" hosted by China Times and China Health Research Institute was held in Beijing. With the topic of "New quality productivity leading change, AI technology empowering innovation and development", this conference brings experts, scholars, entrepreneurs, and relevant industry elites in the field of big health together, to discuss new opportunities for the development of medicine and big health.
Sungen Biomedical was awarded the title of "2024 Top 10 Innovative Pharmaceutical Enterprises" for its excellent scientific research and drug development capabilities, as well as the innovation and potential socio-economic value of the world's first AMI antibody drug SGC001 injection.
Sungen Biomedical, an antibody drug R&D enterprise incubated by Hotgen Biotech, focuses on FIC (First in class) antibody drug discovery, development and commercialization, and is committed to becoming a global leading antibody drug R&D enterprise.
In the process of innovation and development:
Sungen Biomedical won the first prize of Beijing Science and Technology Progress Award 2023;
Sungen Biomedical deeply integrates artificial intelligence algorithms with biopharmacharmacent-based technology through the "X-Gen AI New Drug Discovery and Design Research Center", accelerates the process of new drug discovery and design, and explores to bring more innovative breakthroughs to the medical industry;
Sungen Biomedical won the Ernst & Young Fudan Most Promising Enterprise Award 2024;
Professor Du Jie, co-scientist of Sungen Biomedical and Beijing Institute of Cardiovascular and Vascular Diseases, Capital Medical University, was selected into the list of "Top 2% of Global Scientists with Lifetime Scientific Impact 2024";
Application for clinical trial (IND) of SGC001, the world's first innovative first aid antibody for myocardial infarction, was approved by the US Food and Drug Administration (FDA), making a new breakthrough in innovative drug development;
SGC001 injection obtained the clinical trial implied approval from Center for Drug Evaluation, National Medical Products Administration. The clinical progress is going well. It is expected to provide a safer and more effective treatment for global AMI patients, and has the potential to become a First-in-class drug.
At present, Sungen Biomedical has built a series of international-standard technology platforms. Guided by unmet clinical needs, Sungen has established a number of original biological macromolecular product pipelines with great market potentials, involving the treatment of cardiovascular and cerebrovascular diseases, tumors, autoimmunity and other diseases, and accelerating the construction of new quality productivity driven by innovation to benefit human health.
Photo: Dr. Gao Qi, Deputy general manager, Beijing Sungen Biomedical Technology Co., Ltd.
In the roundtable dialogue session of "What opportunities and challenges are China's innovative pharmaceutical and IVD companies facing in the process of going overseas", Dr. Gao Qi, Deputy general manager, Beijing Sungen Biomedical, said the main driving forces for China's innovative pharmaceutical industry to transform from "input" to "export" include policy support, talent return, technology accumulation and market expansion. Financial market reform and pharmaceutical enterprise innovation promote the rapid development of the industry. These factors have jointly promoted the development of China's innovative pharmaceutical industry, which not only benefits global patients, but also enhances the research & development capabilities and the market of domestic pharmaceutical companies.
However, enterprises also face various challenges and opportunities: technological breakthroughs, international market competition, intellectual property protection and other challenges, as well as policy dividends, international cooperation, and opportunities for increased global market demand. Enterprises need to strengthen innovation, expand the market, balance risks and benefits, and enhance international competitiveness.
"Golden Cane Award" is a health industry award launched by China Times on the platform of "China Health Industry Development Conference". The cane itself has the meaning of help, and the establishment of the Golden Cane Award mainly hopes that winning enterprises continue to make contributions to human health, so that people can live a healthy life without the assistance of the cane. At the same time, it is also hoped that the golden cane will spread positive energy and promote the healthy development of the medical industry.
Updated: Nov 25, 2024
